* QUANTUM GENOMICS *
2006 - IDF
Massy
(near Paris / HQ
Jersey City
USA)
www.quantum-genomics.com Discovery, Drugs
Key words: Academic, Development platform, Co-partnering R&D
Mission: to maximize the developments and discoveries of academic research into breakthrough treatments for human disease, in cardiovascular diseases, neurology and metabolic related diseases
Clients: Pharmaceutical industry
contact@quantum-genomics.com
Age: 6 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Start-up |
Managing Dir.-CEO: Segard (Lionel) [born 1968, Biochemistry, ex-Inserm-Transfert (CEO), IBM, TFSM]
Sc.Dir.-CSO: Riffaud (Jean-Pierre) [Pharm.D., ex-Cellpep, NicOx, Fournier, Debat]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): | Turnover (M€) : 0.019 (2009), 0.016 (2008)
Total funding (M€) : 4.0
Last funding (M€) : 1.0
Focus : Multiple
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2011 .02 | Financing (grant) : 1.0 M€, by ANR, to finance the beginning of the clinical development of QGC 001 | RFIN | [5 years] |
| 2009 .04 | Financing (no interest loan) : 0.7 M€, by OSEO Innovation, to finance the regulatory preclinical development of QGC 001 (the first drug to treat hypertension by targeting Aminopeptidase A) | DEBT | [3 years] |
| 2008 .01 | Acquisition of Eurobiobiz (Clermont-Ferrand), specialized in high-value added project management | ACQ+ | [2 years] |
| 2007 .06 | Partnering research agreement with Inserm and CNRS on their hypertension chemical entity, as QGC001 | R&D | [1 year] |
| 2006 .07 | 1st round-financing : 3.0 M€, led by undisclosed investors | RFINA | [0 year] |
| 2006 .06 | Company founded by US investors (New Jersey), with European HQ and management in Paris region | ORGF | [0 year] | Actualisation / Updating: 9-May-2011 |
|
